Moreover, the therapeutic efficacy of miR-122 in mitigating liver fibrosis is compromised by elevated NEAT1 levels, which in turn increase KLF6 expression in HSCs, ultimately resulting in HSCs activation [34]. The gene discussed is NEAT1; the disease is Hepatic fibrosis.